NEW YORK (GenomeWeb) – Metamark Genetics announced that three Medicare contractors have issued draft local coverage determinations (LCDs) for its ProMark prognostic test for early-stage prostate cancer.
Palmetto GBA, Noridian Healthcare Solutions, and CGS Administrators have all issued draft LCDs proposing reimbursement for the proteomic test.
"These draft LCDs represent another significant milestone for ProMark," Metamark President and CEO Jerry Williamson said in a statement. "The draft LCDs closely follow ProMark's inclusion in the 2016 National Comprehensive Cancer Network Clinical Practice Guidelines in March, further demonstrating the growing adoption of ProMark as a meaningful prognostic tool in the care of patients with clinically localized prostate cancer."
ProMark is a proteomic classifier of biopsied tissue and predicts whether cancer can be managed without aggressive treatment or indicates that therapy may be appropriate. The test is run out of Metamarks' Cambridge, Massachusetts CLIA-certified and CAP-accredited laboratory.
As reported by GenomeWeb, Metamark has seen strong sales of the Promark test since it launched in 2014. In April 2015, the firm signed a deal for Highmark Blue Shield to cover its urology diagnostics.